SCHEMBL458334

SCHEMBL458334

O=C(Nc1nc2ccc(-c3ccncc3)cc2s1)N1CCC(=Cc2ccccn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.51
ABL1 P00519 5/20 0.48
PIK3CG P48736 2/20 0.46
RAB9A P51151 4/20 0.46
HTT P42858 3/20 0.46
TRPV1 Q8NER1 3/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 3/20 0.46
OPRK1 P41145 2/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
CRHBP P24387 1/20 0.45
KMT2A Q03164 1/20 0.45
CRHR2 Q13324 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
PRKCG P05129 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459961 0.91 PIK3CG (0.46) ITKABL1PIK3CGRAB9AHTT
SCHEMBL458913 0.91 PIK3CG (0.56) ITKABL1PIK3CGRAB9AHTT
SCHEMBL458364 0.89 TRPV1 (0.44) ITKABL1PIK3CGRAB9AHTT
SCHEMBL15103274 0.87 NPC1 (0.52) RAB9ANPC1SMN1; SMN2HPGDSPIK3CA
SCHEMBL460334 0.86 TRPV1 (0.47) RAB9AHTTTRPV1NPC1MAPT
SCHEMBL460061 0.86 HPGDS (0.55) RAB9AHTTTRPV1NPC1MAPT
SCHEMBL460519 0.86 PIK3CG (0.58) ABL1PIK3CGRAB9AHTTTRPV1
SCHEMBL458405 0.86 ABL1 (0.47) ABL1PIK3CGTRPV1MAPTKDM4E
SCHEMBL460191 0.84 RAB9A (0.44) ABL1RAB9AHTTTRPV1NPC1
SCHEMBL460598 0.83 DYRK1A (0.52) RAB9AHTTNPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US claimed
EP-2615084-B1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO LTD (JP) 2016-01-06 EP disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
EP-2615084-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS Taiho Pharmaceutical Co., Ltd. (JP) 2013-07-17 EP disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
WO-2012033069-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS 大鵬薬品工業株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR ITK 4779/4885ABL1 2666/4885PIK3CG 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.